Table 1 Demographic and baseline characteristics of participants
Liquid Kaloba® (n = 42) | Liquid placebo (n = 40) | Tablet Kaloba® (n = 26) | Tablet placebo (n = 26) | All participants | |
|---|---|---|---|---|---|
Female | 19/42 (45.2%) | 26/40 (65.0%) | 15/26 (57.7%) | 16/26 (61.5%) | 76/134 (56.7%) |
Mean age (SD) | 56.64 (14.41) | 56.65 (17.24) | 59.23 (12.31) | 57.27 (17.89) | 57.27 (15.52) |
Ethnicity | |||||
➙White | 30/31 (96.8%) | 27/27 (100.0%) | 20/21 (95.5%) | 21/22 (95.5%) | 98/101 (97.0%) |
➙Mixed | 0/31 (0.0%) | 0/27 (0.0%) | 0/21 (0.0%) | 1/22 (4.6%) | 1/101 (1.0%) |
➙Asian/Asian-British | 1/31 (3.2%) | 0/27 (0.0%) | 0/21 (0.0%) | 0/22 (0.0%) | 1/101 (1.0%) |
➙Prefer not to answer | 0/31 (0.0%) | 0/27 (0.0%) | 1/21 (4.6%) | 0/22 (0.0%) | 1/101 (1.0%) |
Employment | |||||
➙Full/part time | 18/31 (58.1%) | 13/26 (50.0%) | 10/21 (47.6%) | 11/22 (50.0%) | 52/100 (52.0%) |
➙Unable to work | 1/31 (3.2%) | 1/26 (3.9%) | 1/21 (4.8%) | 0/22 (0.0%) | 3/100 (3.0%) |
➙Retired | 11/31 (35.5%) | 11/26 (42.3%) | 10/21 (47.6%) | 11/22 (50.0%) | 43/100 (43.0%) |
➙Full time education | 0/31 (0.0%) | 1/26 (3.9%) | 0/21 (0.0%) | 0/22 (0.0%) | 1/100 (1.0%) |
➙Not working for other reasons | 1/31 (3.2%) | 0/26 (0.0%) | 0/21 (0.0%) | 0/22 (0.0%) | 1/100 (1.0%) |
Smoking habits | |||||
➙Never | 15/30 (50.0%) | 11/27 (40.7%) | 7/21 (33.3%) | 10/22 (45.5%) | 43/100 (43.0%) |
➙Past | 14/30 (46.7%) | 14/27 (51.9%) | 13/21 (61.9%) | 8/22 (36.7%) | 49/100 (49.0%) |
➙Current | 1/30 (3.3%) | 2/27 (7.4%) | 1/21 (4.8%) | 4/22 (18.2%) | 8/100 (8.0%) |
Health conditions | |||||
➙Hypertension | 11/42 (26.2%) | 9/40 (22.5%) | 7/26 (26.9%) | 4/26 (15.4%) | 31/134 (23.1%) |
➙CVD | 1/42 (2.4%) | 3/40 (7.5%) | 0/26 (0.0%) | 1/26 (3.9%) | 5/134 (3.7%) |
➙Lung disease/COPD | 0/42 (0%) | 1/40 (2.5%) | 2/26 (7.7%) | 0/26 (0%) | 3/134 (2.2%) |
➙Diabetes | 5/42 (11.9%) | 3/40 (7.5%) | 3/26 (11.5%) | 1/26 (3.9%) | 12/134 (9.0%) |
➙Asthma | 9/42 (21.4%) | 8/40 (20.0%) | 3/26 (11.5%) | 3/26 (11.5%) | 23/134 (17.2%) |
Antibiotic Prescription | |||||
➙No | 25 (59.5%) | 29 (72.5%) | 12 (46.2%) | 14 (53.8%) | 80/134 (59.7%) |
➙Delayed Use | 3 (7.1%) | 3 (7.5%) | 7 (26.9%) | 8 (30.8%) | 21/134 (15.7%) |
➙Immediate Use | 14 (33.3%) | 8 (20.0%) | 7 (26.9%) | 4 (15.4%) | 33/134 (24.6%) |